氨磷汀联合沙利度胺治疗骨髓增生异常综合征疗效观察  

Effects of Amifostine Combined with Thalidomide on Patients with Myelodysplastic Syndrome

作　　者：杨国华[1] 钱锡峰[1] 庄芸[1] 沈云峰[1] 

机构地区：[1]江苏省无锡市人民医院,无锡214023

出　　处：《中国药物评价》2012年第2期120-122,共3页Chinese Journal of Drug Evaluation

摘　　要：目的:观察氨磷汀联合沙利度胺治疗骨髓增生异常综合征(MDS)的临床疗效及毒副作用。方法:对23例MDS患者给予氨磷汀及沙利度胺治疗。结果:CR10例(43.5%),PR4例(17.4%),NR9例(39.1%)。总反应率60.9%,7例伴有粒系明显改善,4例伴血小板改善。主要毒副作用是恶心呕吐等胃肠道反应,但均能耐受。结论:氨磷汀联合沙利度胺治疗MDS是一种有效的方法,值得临床进一步应用研究。Objective： To investigate the efficacy and toxicity of amifostine（AMF） combined with thalidomide on patients with myelodysplastic syndrome（MDS）. Methods： 23 MDS patients were treated with AMF and thalidomide. Results： The overall re- sponse rate was 60. 9%, including complete response （CR） in 10（43. 5% ） , partial response（PR） in 4（ 17.4% ） , No response （NR） was 9 cases（39. 1% ）. 7 cases attained hematological obvious improvement in leukocytes and 4 cases attained hematological improvement in platelets. The main side reaction was usually discomfort of digestive system, but all patients can endure. Conclu- sions ： Aamifostine plus thalidomide may have a good therapeutic effects for MDS patients, and its clinical curative still needs further evaluation.

关 键 词：氨磷汀 沙利度胺 骨髓增生异常综合征 联合用药 

分 类 号：R551.3[医药卫生—血液循环系统疾病]